Related Experiment Video

Updated: Feb 8, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.5K

Current medical management of patients with poor-risk metastatic germ-cell tumors

Costantine Albany1

  • 1Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Current Opinion in Urology
|July 7, 2018
PubMed
Abstract

Insights

Treatment for poor-risk germ-cell tumors (GCTs) is improving, with promising results from dose-dense chemotherapy regimens like BEP and TIP in early trials. Further research is needed to confirm these advances for better GCT survival rates.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Germ-cell tumors (GCTs) have high cure rates, but metastatic poor-risk GCTs have a 5-year survival rate below 50%.
  • Optimizing treatment for poor-risk GCT is crucial to improve patient outcomes.

Purpose of the Study:

  • To review recent advancements in the treatment of poor-risk germ-cell tumors.
  • To highlight key discoveries and ongoing research in GCT management.

Main Methods:

  • Review of ongoing and recently published clinical trials.
  • Analysis of data from phase II trials of novel chemotherapy regimens.

Main Results:

  • Phase II trials of dose-dense multidrug regimens, including accelerated bleomycin, etoposide, and cisplatin (BEP) and paclitaxel, ifosfamide, and cisplatin (TIP), show promising results.
  • Positive phase III data are still pending for these novel regimens.

Conclusions:

  • Four cycles of BEP or etoposide, ifosfamide, cisplatin (VIP) remain the standard of care for poor-risk GCT.
  • Significant outcome disparities exist between treatment centers; referral to centers of excellence is recommended.

More Related Videos

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

6.0K
An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth09:14

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

16.3K

Related Concept Videos

Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
261
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
218
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
365
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
342
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
312
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
458